Stem Cells Archives | Page 123 of 201

Dubai First to Launch Innovative Stem Cell Therapy for Joint Disease

November 21, 2017 By Cade Hildreth, Founder & President Leave a Comment

UAE residents will no longer need to travel abroad to receive stem cell therapy for joint disease

Dubai, United Arab Emirates, November 21 2017 – Bioscience Clinic FZ LLC located in Dubai Healthcare City is pleased to launch to its latest innovative stem cells therapy for treatment of joint disease. Established since 2012, Bioscience Clinic is Dubai’s first and most advanced clinic to use stem cells taken from adipose tissue in a variety of clinical applications. Its latest therapy was first introduced in Europe by Bioscience Institute, a Bioscience Clinic sister company. [Read more…]

Cynata Therapeutics Releases Investor Presentation Featuring Operational Progress

November 17, 2017 By Cade Hildreth, Founder & President Leave a Comment

Melbourne, Australia; 15 November 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to release a new investor presentation to be presented at a series of upcoming institutional investor meetings.

Paul Wotton (Cynata Chairman) and Ross Macdonald (Cynata CEO) will be meeting with a series of new and existing institutional investors prior to the upcoming AGM on November 17.

Cynata Therapeutics provides investors with excellent exposure to a rapidly growing regenerative medicine and stem cell sector via its patented CymerusTM technology, a platform able to manufacture mesenchymal stem cells (MSCs) at a commercial scale. The new investor presentation highlights Cynata Therapeutics’ compelling investment case and provides information about the Company’s progress. [Read more…]

Enrollment of First Cohort Completed with Eighth Participant Dosed in Cynata’s World First Clinical Trial

November 15, 2017 By Cade Hildreth, Founder & President Leave a Comment

MELBOURNE, Australia, Nov. 15, 2017 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to provide an update on the progress of the clinical trial of its lead Cymerus™ mesenchymal stem cell (MSC) product CYP-001. [Read more…]

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

November 8, 2017 By Cade Hildreth, Founder & President Leave a Comment

London, UK and Montreal, Canada, November 8, 2017 (Newswire) –Fortuna Fix (“Fortuna”), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming (“drNPCs”) to replace lost neuronal tissue in neurodegeneration and neurotrauma.
[Read more…]

Pluristem Partners with Tel Aviv Sourasky Medical Center for Phase I/II Trial in Steroid-Refractory Chronic GvHD

November 6, 2017 By Cade Hildreth, Founder & President Leave a Comment

Tel Aviv Sourasky Medical Center will act as the sponsor of the study
PLX-PAD cells have demonstrated efficacy in preclinical models of GvHD

HAIFA, Israel, Nov. 06, 2017 — Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has signed an agreement with Tel Aviv Sourasky Medical Center (Ichilov Hospital) to conduct a Phase I/II trial in PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-versus-Host-Disease (GvHD).

The trial will be an investigator initiated study. As such, Tel Aviv Sourasky Medical Center will support the study and will be responsible for its design and implementation. Dr. Ron Ram, Director of the Hematology Blood and Marrow Stem Cell Transplantation Unit for the Tel Aviv Sourasky Medical Center will act as principal investigator.

GvHD is a potentially lethal complication of hematopoietic cell transplantation (HCT) from a donor. When a patient receives a donor’s stem cells, the transplanted cells identify the patient’s body as foreign and attack it. The chronic form of GvHD occurs at least 100 days following the transplantation. The GvHD market is predicted to exceed $500 million by 2023. [Read more…]